The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial

JACC: Cardiovascular Interventions

Volumn 2, Issue 3, 2009, Pages 205-214

  Verheye, Stefan ^a   Agostoni, Pierfrancesco ^a   Dawkins, Keith D ^b   Dens, Joseph ^c   Rutsch, Wolfgang ^d   Carrie, Didier ^e   Schofer, Joachim ^f   Lotan, Chaim ^g   Dubois, Christophe L ^h   Cohen, Sidney A ⁱ   Fitzgerald, Peter J ^j   Lansky, Alexandra J ^k  

^a MIDDELHEIM HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c Oost Limburg Hospital   (Belgium)

^d HUMBOLDT UNIVERSITY   (Germany)

^e CHU RANGUEIL   (France)

^f UNIVERSITY HEART CENTER HAMBURG   (Germany)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^k NewYork Presbyterian Hospital   (United States)

more..

Author keywords

coronary artery disease; paclitaxel eluting stent; pimecrolimus eluting stent; restenosis

Indexed keywords

CHROMIUM; COBALT; PACLITAXEL; PIMECROLIMUS; POLYMER; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; ANALOGS AND DERIVATIVES; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 62149128208     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.12.011     Document Type: Article

References (22)

1. Silber S., and EuroSTAR II. The European Randomized CoStar Trial: Cobalt-Chromium Paclitaxel-eluting Stent vs. identical BMS. Presented at Transcatheter Cardiovascular Therapeutics 2007. http://www.crtonline.org/flash.aspx?PAGE_ID=4748 Accessed June 1, 2008
2. Krucoff M.W., Kereiakes D.J., Petersen J.L., et al., COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent with Antiproliferative for Restenosis) II study. J Am Coll Cardiol 51 (2008) 1543-1552
3. Nikol S., Huehns T.Y., and Höfling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 123 (1996) 17-31
4. Gisondi P., Ellis C.N., and Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 59 (2005) 969-974
5. Dobesh P.P., Stacy Z.A., Ansara A.J., and Enders J.M. Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease. Pharmacotherapy 24 (2004) 1554-1577
6. Costa M.A., and Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 111 (2005) 2257-2273
7. Van der Zwet P., and Reiber J. A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results. J Am Coll Cardiol 24 (1994) 216-224
8. Lansky A.J., Dangas G., Mehran R., et al. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol 39 (2002) 274-280
9. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
10. Ako J., Morino Y., Honda Y., et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 46 (2005) 1002-1005
11. Kereiakes D.J., Kuntz R.E., Mauri L., and Krucoff M.W. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 45 (2005) 1206-1212
12. Mauri L., Orav E.J., and Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 111 (2005) 3435-3442
13. Cutlip D.E., Windecker S., Mehran R., et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
14. Krucoff J.J. The CoStar bioabsorbable polymer-based paclitaxel-eluting stent: COSTAR II postmortem. Presented at the 2007 Transcatheter Cardiovascular Therapeutics (TCT) Conference Proceedings, held in Washington (October 20-25, 2007). http://www.tctmd.com/tct2007.aspx?id=68284 Accessed August 13, 2008
15. Waksman R., Pakala R., Baffour R., et al. Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. Cardiovasc Revasc Med 8 (2007) 259-274
16. Berg R., Aragon J., Royter V., et al. Pimecrolimus and dual pimecrolimus-paclitaxel eluting stents decrease neointimal proliferation in a porcine model. Catheter Cardiovasc Interv 70 (2007) 871-879
17. Schwartz R.S., Edelman E.R., Carter A., Chronos N., Rogers C., et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
18. Ribichini F., Tomai F., Paloscia L., et al., DESIRE Investigators. Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart 93 (2007) 598-600
19. van der Hoeven B.L., Pires N.M., Warda H.M., et al. Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients. Int J Cardiol 124 (2008) 166-171
20. Hoffmann R., Radke P.W., Ortlepp J.R., et al. Intravascular ultrasonic comparative analysis of degree of intimal hyperplasia produced by four different stents in the coronary arteries. Am J Cardiol 94 (2004) 1548-1550
21. Dawkins K., Verheye S., Shuhlen H., et al. The European Cobalt Stent with Antiproliferative for Restenosis trial. (EUROSTAR): 12 month results. EuroIntervention 3 (2007) 82-88
22. Serruys P.W., Sianos G., Abizaid A., et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46 (2005) 253-260